Eikon Therapeutics reports Q2 2026 results with seven ESMO abstracts and melanoma trial progress

Eikon Therapeutics reported second quarter 2026 results on August 13, 2026, alongside clinical updates across its oncology pipeline. The company said seven abstracts were accepted for presentation at the ESMO Congress 2026, covering clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005.¹

On the lead program, EIK1001, an independent Data Monitoring Committee completed a first interim analysis of the TeLuRide-006 Phase 2/3 registrational trial in first-line advanced melanoma on August 11, 2026, selecting a single dosing regimen for expansion and recommending the study continue as planned.¹ Separately, Eikon announced dosing of the first patient in TeLuRide-008, a Phase 2/3 registrational trial of EIK1001 with pembrolizumab and chemotherapy in treatment-naive stage 4 NSCLC patients, on July 27, 2026.¹

For the PARP1 inhibitor programs, Eikon is enrolling an additional Cohort 1D evaluating EIK1003 with paclitaxel and platinum-based chemotherapy in ovarian cancer, with site selection completed and enrollment ongoing.¹ The company is also testing two dose levels of EIK1003 monotherapy, 20 mg and 60 mg, with about 30 PARPi-naive, HER2-negative breast cancer patients expected per dose level to determine the Phase 2 dose.¹ For EIK1005, targeting the WRN helicase, the first patient in the Phase 1/2 dose-escalation trial was dosed in January 2026.¹ For the AR antagonist EIK1006, Eikon expects to submit an IND by the end of 2026.¹

On financials, Eikon had $531.2 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it expects will fund operations into the second half of 2027.¹ Net loss attributable to common stockholders was $88.4 million for the quarter, compared with $105.2 million a year earlier.¹